An interventional study of Artacent Human Amniotic Membrane and Standard of Care in Venous Ulcer and Foot Ulcer, Diabetic, sponsored by Tides Medical. Status unknown at 7 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-13.
Sponsored by Tides Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Varicose Ulcer with a site in United States — 33 open to participants now, 43 under way, 4 of them phase 3. Varicose Ulcer · United States.
Among the 155 studies in Varicose Ulcer with a site in United States, this one is the 41st largest by planned enrollment of the 132 interventional ones that give a count, is one of 9 that started in 2016, is one of 79 with no phase, and was the 68th registered.
371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.
Browse Varicose Ulcer studies →33 of the 155 studies in Varicose Ulcer with a site in United States are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in United States
Ages 18+
NuScience Medical Biologics, LLC · Sites in United States
Ages 18+
BioLab Holdings · Sites in United States
Ages 18+
Capsicure, LLC · Sites in United States
Ages 18+
BioLab Holdings · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 19 · Phase 3 10 · Phase 4 15
First in 2000; this study’s year is marked. 9 started in 2016.
This study's planned enrollment of 134 is above the median of 60 across 310 interventional studies indexed under Varicose Ulcer.
Median enrollment 53 across the 132 interventional studies, 300 across the 23 observational. Of the 87 that completed or were terminated, 34 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 155 have an industry lead sponsor. The 10 most frequent:
Tides Medical is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Tides Medical has 1 study filed under Varicose Ulcer — fewer than ten, so there is no comparison to draw.
22 of the studies in Varicose Ulcer with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06568627Phase 3MediWound LtdA Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | 2026-12 |
| NCT06707103Phase 3TR TherapeuticsTissue Repair Gel in Venous Leg Ulcers in AU/US | 2026-12 |
| NCT06489028Phase 3RHEACELL GmbH & Co. KGAllogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III) | 2027-04 |
| NCT06697925Kerecis Ltd.Evaluating the Durability of Closure for Venous Leg Ulcers | 2026-11 |
| NCT06693570Kerecis Ltd.Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers | 2026-11 |
Add all 22 to your calendar (.ics) → With an account.
Among the 155 studies in Varicose Ulcer with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the proportion of patients who have wound closure within 12 weeks as well as the time to wound closure in patients receiving Artacent™ versus standard of care for treatment of non-healing lower extremity wounds. The recurrence of healed wounds will be assessed at 6 months via a telephone survey
This study is to document the efficacy of Artacent™ Human Amniotic Membrane (Artacent) in the treatment of diabetic and vascular lower extremity ulcers. The study will add to the currently available literature by also assessing the impact of treatment on quality of life and on heal economic outcomes. Finally the study will follow patients for longer than previous studies and will obtain data on healing and recurrence at 6 months.
The objectives of this study are 1) to compare Artacent to standard of care (SOC) in the treatment of non-healing lower extremity ulcers and 2) to evaluate the impact of treatment on patient quality of life. Health economic outcomes will also be collected. The proportion of patients receiving Artacent who have wound closure with 12 weeks will be compared to those patients receiving SOC only will be compared. A comparison of time to wound closure will also be compared between the two populations.
Patients who are randomized to the SOC group (control) and require further treatment at 12 weeks due to incomplete wound healing, may receive treatment with Artacent if the investigator determines that to be a potentially beneficial option.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the Artacent group will receive standard of care (off-loading with a removable cast walker and non-adherent dressings in addition to debridement and use of moisture retentive dressing) and the application of the Artacent amniotic allograft once every two weeks for up to 5 applications or until the ulcer has healed.
Other: Artacent Human Amniotic Membrane
Patients randomized to standard of care will receive off-loading with a removable cast walker and non-adherent dressings (e.g. Adaptic) in addition to debridement and use of moisture retentive dressings. An outer dressing will also be applied.
Procedure: Standard of Care
Double layer dehydrated amnion product
Also known as: Amniotic tissue allograft, Amniotic placental membranes
Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
Also known as: Debridement, Off-loading, non-adherent dressings
Wound closure
100% re-epithelialization of the wound without drainage or need for use of a dressing
Time frame: 12 weeks
Time to wound closure
# of days to 50% or greater closure
Time frame: 12 weeks
Ulcer recurrence
Telephone survey to capture number of ulcer recurrences and treatment
Time frame: 6 months
Quality of Life
EQ-5D survey
Time frame: 12 weeks
Impact of Treatment on Return to Work
Employment status e.g. full-time, part-time, retired, unemployed, etc.
Time frame: 12 weeks
Time to full weight bearing status
Ability of the subject to bear full weight and the time to full weight bearing
Time frame: 12 weeks
Adverse Events and Secondary Treatments
Time frame: 12 weeks
Number of grafts and graft size(s)
Number and size of grafts used at each application will be collected.
Time frame: 12 weeks
Health economic outcomes
Collection of de-identified Explanation of Benefits (EOB) and/or submitted claims and/or documentation of procedures via CPT coding.
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Sep 2016, a primary completion of Dec 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.